Abstract:The presence of EGFR activating mutations and ALK chromosomic rearrangements with corresponding tyrosine kinase inhibitors (TKIs) has revolutionized the treatment strategies of patients with non-small cell lung cancer (NSCLC). Although tremendously initial response and manageable toxicity profiles, acquired resistance inevitably develops after approximately 1 year treatment with EGFR-TKIs (erlotinib and gefitinib) and ALK inhibitor (crizotinib). Encouragingly, third-generation EGFR-TKIs including AZD9291, CO1686 and brigatinib have showed striking efficacy overcoming acquired resistance driven by T790M secondary mutations. Other novel third-generation EGFR-TKIs such as ASP8274, EGF816, PF-06747775 and avitinib are also being investigated in early-stage clinical trials and the survival and safety data will be released in the near future. Another promising novel EGFR-TKI, namely AZD3759 has showed promising response in patients with brain metastases and leptomeningeal disease. Recently, EAI045, an EGFR allosteric inhibitor, in combination with cetuxmab exhibit antitumor activity in mouse models of lung cancer driven by L858R/T790M/C797S, a resistant mutation of AZD9291. Meanwhile, second-generation ALK inhibitors (ceritinib and alectinib) have entered clinical applications for NSCLC patients with ALK rearrangements after failure of crizotinib and third-generation ALK inhibitors (lorlatinib and ASP3026) are also being evaluated in clinical trials overcoming known ALK resistant mutations. On the other hand, with the development of high-throughput sequencing, called next-generation sequencing (NGS) and genomic technologies, more novel molecular targets such as MET 14 exon skipping splicing mutations have been identified as potential therapeutic targets and simultaneously analyzing hundreds of molecular alterations have turned out reality with limited tumor tissues. In the recent years, the emergence of numbers of oncogenic drivers other than EGFR mutations and ALK rearrangements has divided NSCLC into multiple distinct subtypes amenable to corresponding targeted therapy. For instance, dabrafenib either as monotherapy or in combination with MEK inhibitor (trametinib) has displayed promising antitumor activity and manageable safety profile in patients with BRAF V600E mutations, accounting for around 1.4% of patients with NSCLC. Other novel molecular targets maybe serving as oncogenic drivers including mutations in HER2 (neratinib and pyrotinib) and PI3KCA (BKM120 and GDC0941), ROS1 (entrectinib, foretinib and lorlatinib), RET (XL184) and NTRK (entrectinib) rearrangements and FGFR1 gene amplification (AZD4547, Lenvatinib and FP-1039) are being evaluated either in preclinical settings or early-stage clinical trials. Section not applicable Section not applicable Section not applicable

EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer

Epidermal Growth Factor Receptor‐tyrosine Kinase Inhibitor Therapy is Effective As First‐line Treatment of Advanced Non‐small‐cell Lung Cancer with Mutated EGFR: A Meta‐analysis from Six Phase III Randomized Controlled Trials

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature

Progress on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor for Treatment of Advanced Non-Small Cell Lung Cancer

Targeted Therapy for Non-Small-cell Lung Cancer Using EGFR-TKIs

First-Generation EGFR-TKI Plus Chemotherapy Versus EGFR-TKI Alone As First-Line Treatment in Advanced NSCLC with EGFR Activating Mutation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Progress of EGFR-TKIs in Non-small Cell Lung Cancer

Application of Immune Checkpoint Inhibitors in EGFR-mutant Non-Small-cell Lung Cancer: from Bed to Bench

An Updated Network Meta-Analysis of EGFR-TKIs and Combination Therapy in the First-Line Treatment of Advanced EGFR Mutation Positive Non-Small Cell Lung Cancer

Application of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor As the First-line Therapy in Patients with Advanced Non-small Cell Lung Cancer

Erlotinib in the Treatment of Advanced Non-Small Cell Lung Cancer: an Update for Clinicians

EGFR-TKI Resistance in NSCLC Patients: Mechanisms and Strategies.

Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) Inhibitors Plus Antiangiogenic Agents as First-Line Treatments for Patients With Advanced<i>EGFR</i>-Mutated Non-small Cell Lung Cancer: A Meta-Analysis

Critical Appraisal of the Role of Gefitinib in the Management of Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Precision First-Line Therapy for Advanced Non-Small-cell Lung Cancer Patients Harboring EGFR Mutation

PUB007 Novel TKIs in Non-Small Cell Lung Cancer

Efficacy And Safety Of Epidermal Growth Factor Receptor (Egfr) Inhibitors Plus Antiangiogenic Agents As First-Line Treatments For Patients With Advancedegfr-Mutated Non-Small Cell Lung Cancer: A Meta-Analysis

The role of angiogenesis inhibitors associated with tyrosine kinase inhibitors in the first-line treatment for EGFR-mutated advanced lung cancer

The advance of the third‑generation EGFR‑TKI in the treatment of non‑small cell lung cancer (Review)

Osimertinib for Egfr T790m Positive Non-Small Cell Lung Cancer-Making It Happen, Turning Good Idea into Great Results

Critical appraisal of the role of gefitinib in the management of locally advanced or metastatic non-small cell lung cancer.